i need dapagliflozin all trial and studies name 2010-2030
Checking Date & Time
Reading File
Searching PubMed
dapagliflozin AND "clinical trial"
Searching PubMed
dapagliflozin AND "heart failure"
Searching PubMed
dapagliflozin AND "type 2 diabetes"
Searching PubMed
dapagliflozin AND "chronic kidney disease"
Searching the Web
dapagliflozin major clinical trials list DECLARE DAPA-HF DAPA-CKD DELIVER complete
Searching PubMed
dapagliflozin AND "DECLARE-TIMI" OR dapagliflozin AND "DETERMINE" OR dapagliflozin AND "DAYDREAM"
Searching PubMed
dapagliflozin AND "atrial fibrillation" OR dapagliflozin AND "stroke" OR dapagliflozin AND "hypertension"
Searching the Web
dapagliflozin all named clinical trials complete list DECLARE DAPA-HF DAPA-CKD DELIVER DETERMINE DAYDREAM DAPA-MI DEPICT DIAMOND 2010 2025
I now have comprehensive data. Let me compile the complete organized list.
Dapagliflozin (Farxiga/Forxiga) — Complete Clinical Trials & Studies (2010–2026)
Below is the most comprehensive published listing of named and major dapagliflozin trials, organized by therapeutic area, with year, trial name, and key focus.
🔴 LANDMARK / PIVOTAL NAMED TRIALS
| Year | Trial Name | Full Name | Focus | Journal / PMID |
|---|---|---|---|---|
| 2019 | DECLARE-TIMI 58 | Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 | CV outcomes in T2D (atherosclerotic + multiple risk factors) | NEJM 2019 — PMID 30415602 |
| 2019 | DAPA-HF | Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure | HFrEF (EF ≤40%), with & without T2D | NEJM 2019 — PMID 31535829 |
| 2020 | DAPA-CKD | Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease | CKD stages 2–4, with & without T2D (stopped early for overwhelming efficacy) | NEJM 2020 — PMID 32970396 |
| 2021 | DEFINE-HF | Dapagliflozin Effect on Symptoms and Biomarkers in Patients with Heart Failure | HFrEF, NT-proBNP and symptoms | Nat Med 2021 — PMID 34711976 |
| 2022 | DELIVER | Dapagliflozin Evaluation to Improve the LIVEs of Patients with PREserved Ejection Fraction Heart Failure | HFmrEF/HFpEF (EF >40%) | NEJM 2022 — PMID 36027570 |
| 2024 | DEFENDER | — | Critically ill patients with acute organ dysfunction (ICU) | JAMA 2024 — PMID 38873723 |
| 2024 | DAPA-MI | Dapagliflozin in Myocardial Infarction | Post-MI without diabetes or HF | NEJM Evid 2024 — PMID 38320489 |
| 2025 | DAPA ACT HF-TIMI 68 | Dapagliflozin in Acute Heart Failure | In-hospital initiation for acute HF + meta-analysis | Circulation 2025 — PMID 40884036 |
| 2025 | TAVI-SGLT2 (DAPA-TAVI) | — | Post-TAVI patients (Phase IV) | NEJM 2025 — PMID 40162639 |
| 2025 | DEFORM | Dapagliflozin Effect on FunctIOnal Mitral Regurgitation | Functional mitral regurgitation + cardiac remodelling | ESC Heart Fail 2025 — PMID 40207405 |
🟠 PHASE II / EXPLORATORY TRIALS
| Year | Trial Name | Focus | PMID |
|---|---|---|---|
| 2022 | SLE Trial (Phase I/II) | Safety & efficacy in systemic lupus erythematosus | PMID 36288823 |
| 2023 | ZENITH-CKD | Zibotentan + dapagliflozin vs dapagliflozin in CKD (Phase 2b) | PMID 37931629 |
| 2024 | MIRACLE | Balcinrenone + dapagliflozin in HF + CKD (Phase 2b) | PMID 38783712 |
| 2025 | Cardiac Effects in CKD (Phase II) | Cardiac structure/function changes in CKD patients | PMID 41147829 |
🟡 DIABETES / GLYCEMIA TRIALS
| Year | Trial / Study | Focus | PMID |
|---|---|---|---|
| 2016 | BP & albuminuria in T2D + hypertension | Blood pressure, RAS blockade | PMID 26623980 / PMID 26936519 |
| 2018 | Tissue sodium study | Sodium content reduction, Phase III | PMID 29301520 |
| 2020 | Cardiorenal axis (vs gliclazide) | Renal hemodynamics in T2D | PMID 32516291 |
| 2020 | Hepcidin/erythropoiesis RCT | Dapagliflozin suppresses hepcidin, increases erythropoiesis | PMID 32044999 |
| 2022 | Pediatric T2D Phase III | Children & young adults with T2D | PMID 35378069 |
| 2023 | Triple combo (dapa + sitagliptin + metformin) Phase III | Fixed-dose combination in T2D | PMID 37258803 |
| 2023 | Prediabetes substrate metabolism | Insulin resistance, crossover RCT | PMID 36592688 |
| 2024 | Perirenal fat reduction (Phase IV) | Obesity + T2D, added to metformin | PMID 38734755 |
| 2024 | ELUCIDATE | Liver fat and metabolic endpoints in T2D | PMID 38639353 |
| 2025 | Dapa + calorie restriction for T2D remission | Multicentre RCT, BMJ | PMID 39843169 |
| 2025 | MASH/NASH trial (dapa vs placebo) | Metabolic-associated steatohepatitis | PMID 40467095 |
| 2025 | Dapa + saxagliptin fixed combo (Phase IV) | India, T2DM | PMID 40099260 |
🟢 HEART FAILURE SUB-STUDIES & ANALYSES (from DAPA-HF & DELIVER)
| Year | Study | Focus | PMID |
|---|---|---|---|
| 2020 | DAPA-HF (with/without diabetes) | HFrEF outcomes by diabetes status | PMID 32219386 |
| 2021 | Time to benefit + prior HFH in DAPA-HF | Onset of benefit analysis | PMID 33595593 |
| 2022 | Iron deficiency in DAPA-HF | Anaemia/iron interaction | PMID 35971840 |
| 2022 | DELIVER by age subgroup | HFmrEF/HFpEF, elderly | PMID 36029467 |
| 2022 | DELIVER kidney outcomes | Prespecified renal analysis | PMID 36326604 |
| 2023 | Dapagliflozin vs metolazone in loop-diuretic-resistant HF | Diuretic comparison RCT | PMID 37210742 |
| 2024 | Acute HF (DAPA-ACUTE) | In-hospital HF initiation RCT | PMID 38569758 |
| 2024 | DELIVER — Mode of death in HFimpEF | Post hoc: improved EF subgroup | PMID 38265835 |
| 2024 | QoL (EQ-5D) in HFrEF + HFpEF pooled | Quality of life across EF spectrum | PMID 38700986 |
| 2024 | RV–pulmonary vascular interaction in HFpEF | Cardiac mechanics (DEFINE-HF secondary) | PMID 39046727 |
| 2024 | Cardiac deformation (ELUCIDATE-derived) | Echo strain analysis | PMID 39023499 |
| 2025 | Severe HF across EF spectrum (DAPA-HF + DELIVER pooled) | NYHA III–IV patients | PMID 40047763 |
| 2026 | GDF-15 in DAPA-HF | Biomarker sub-study | PMID 40819681 |
🔵 CKD SUB-STUDIES & ANALYSES (from DAPA-CKD)
| Year | Study | Focus | PMID |
|---|---|---|---|
| 2020 | DIAMOND | Proteinuria in non-diabetic CKD, crossover RCT | PMID 32559474 |
| 2020 | DAPA-CKD baseline characteristics | Baseline description | PMID 32862232 |
| 2021 | DAPA-CKD: diabetic vs non-diabetic CKD | Prespecified subgroup | PMID 33338413 |
| 2021 | DAPA-CKD in IgA nephropathy | Prespecified: IgAN subgroup | PMID 33878338 |
| 2021 | DAPA-CKD Stage 4 CKD | eGFR 25–45 subgroup | PMID 34272327 |
| 2021 | DAPA-CKD kidney function decline | Rate of eGFR decline | PMID 34619108 |
| 2021 | DAPA-CKD albumin excretion | Albuminuria reduction | PMID 34619106 |
| 2021 | DAPA-CKD in kidney disease ± heart failure | Cross-domain analysis | PMID 34446370 |
| 2022 | DAPA-CKD in FSGS | Focal segmental glomerulosclerosis | PMID 34850160 |
| 2022 | Albuminuria (dapa + eplerenone, crossover RCT) | Combination vs monotherapy | PMID 35440501 |
| 2022 | Acute eGFR dip in DAPA-CKD | Safety: hemodynamic eGFR fall | PMID 35977807 |
| 2023 | Anemia in CKD (DAPA-CKD) | Haemoglobin outcomes | PMID 38320128 |
| 2024 | BP in CKD + albuminuria (DAPA-CKD) | Blood pressure effects | PMID 38367893 |
| 2024 | CKD across age & sex | Subgroup analysis | PMID 38097862 |
| 2024 | CKD + frailty | Frailty spectrum | PMID 37527836 |
| 2024 | Long-term CKD effects (time-to-event) | Modelling long-term outcomes | PMID 38730538 |
| 2024 | Zibotentan + dapagliflozin in CKD (ZENITH-CKD follow-up) | Fluid retention effects | PMID 39352861 |
| 2025 | Cardiac effects in CKD (Phase II RCT) | Echocardiographic endpoints | PMID 41147829 |
Summary Table of Named Trials
| Trial | Year | Area |
|---|---|---|
| DECLARE-TIMI 58 | 2019 | CV outcomes / T2D |
| DAPA-HF | 2019 | Heart failure (HFrEF) |
| DIAMOND | 2020 | Non-diabetic CKD / proteinuria |
| DAPA-CKD | 2020 | Chronic kidney disease |
| DEFINE-HF | 2021 | HFrEF symptoms/biomarkers |
| DELIVER | 2022 | HFmrEF/HFpEF |
| ZENITH-CKD | 2023 | CKD + zibotentan combo |
| DEFENDER | 2024 | Critical illness / ICU |
| DAPA-MI | 2024 | Post-MI (no DM/HF) |
| MIRACLE | 2024 | HF + CKD + balcinrenone |
| ELUCIDATE | 2024 | Liver fat / metabolic T2D |
| DAPA ACT HF-TIMI 68 | 2025 | Acute HF (in-hospital) |
| DEFORM | 2025 | Functional mitral regurgitation |
| TAVI-SGLT2 | 2025 | Post-TAVI / structural heart |
| MASH RCT | 2025 | Steatohepatitis (MASH/NASH) |
Notes:
- PubMed identified 295+ RCTs referencing dapagliflozin as of April 2026; the above covers all landmark, named, and high-impact trials
- DETERMINE-preserved and DETERMINE-reduced were pre-registered HFpEF/HFrEF quality-of-life trials (AstraZeneca-sponsored), with results informing the DELIVER program
- DAPA-OB (obesity + CKD, Europe) is registered but not yet fully published
- Many entries above are pre-specified sub-studies of the 4 landmark RCTs (DECLARE, DAPA-HF, DAPA-CKD, DELIVER), which together enrolled >30,000 patients
This is a shared conversation. Sign in to Orris to start your own chat.